Product Images Donepezil Hydrochloride

This appears to be a graph that represents the change from baseline in the ADCS-ADL score (a clinical assessment tool) for patients receiving either donepezil hydrochloride 10mg/day or placebo. The graph shows data points at 3 and 6 months of drug treatment. The mean values for each group are not available from the text.*

The text appears to be a graph or chart displaying data related to a study on the effects of Donepezil Hydrochioride 10mg per day on patients compared to the placebo, where the cumulative percentage of patients is being plotted against the ADSC-ADL change from the baseline. Without additional context or labels, it is difficult to provide a more detailed description.*

This text seems to be a package label for Donepezil Hydrochloride tablets, USP 5mg. The label includes information such as the manufacturer (Vangard), the lot number (7951), and instructions for storage. There are multiple repetitions of the same text, indicating that this is a label that has been copied or printed multiple times.*

This is a medication package containing Donepezil hydrochloride tablets of 5 and 10mg strength. The tablets should be kept stored at 20-25°C (38-77°F) and below room temperature. It includes a NDC number 33342-026-10 and the manufacturer is Macleods. Dosage information can be found in the package insert. This package is for institutional use only and has a lot number 2M2-1 and expiration date mentioned as 11/13. The remaining text is not interpretable.*

This is a multi-page document containing information about a medication called Donepezil Hydrochloride Tablet USP 10 mg. The packaging is labeled as "Pig By Vangard, Glasgow, KY 42141". This medication appears to have lot number 7952 and is for institutional use only. The document also contains a National Drug Code (NDC) and instructions for storage.*

The text describes a graph displaying the ADAS-cog Change from Baseline over time for different drug treatments (Donepezil Hydrochloride 10mg/day + Ginicai, Donepezil Hydrochloride 5mg/day, and Placebo). The x-axis shows the weeks of drug treatment and the y-axis shows the mean ADAS-cog change from baseline. The graph shows a clinical improvement with Donepezil Hydrochloride 10mg/day + Ginicai treatment after 12 weeks, whereas there is no significant change in the other treatment groups.*

This text appears to be a comparison of the effects of Donepezil and Placebo on patients with ADAS-cog. The table shows the results of the treatment group and placebo in percentages for 5mg/day, 10mg/day, and placebo. There is a change from baseline with varying degrees, 7 points, 4 points or no change. The text seems to be part of a scientific report, possibly a clinical trial.*

This appears to be a table or graph displaying the percentage of patients taking Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo, categorized by their improvement as Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, or Markedly Worse based on the CIBIC-plus Rating.*

The graph shows the cumulative percentage of patients who underwent treatment with Donepezil Hydrochloride 10 mg/day versus placebo. The effectiveness of the treatment is measured by the SIB (Severe Impairment Battery) change from baseline. The x-axis shows the timeline, ranging from 0 to 75 weeks. The y-axis shows the cumulative percentage of patients, ranging from 0% to 100%. This graph can be used to compare the progress of treatment over time between the two groups.*